» Articles » PMID: 36645384

Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity Against Influenza

Overview
Journal J Immunol
Date 2023 Jan 16
PMID 36645384
Authors
Affiliations
Soon will be listed here.
Abstract

Overcoming interfering impacts of pre-existing immunity to generate universally protective influenza A virus (IAV)-specific T cell immunity through vaccination is a high priority. In this study, we passively transfer varied amounts of H1N1-IAV-specific immune serum before H1N1-IAV infection to determine how different levels of pre-existing Ab influence the generation and protective potential of heterosubtypic T cell responses in a murine model. Surprisingly, IAV nucleoprotein-specific CD4 and CD8 T cell responses are readily detected in infected recipients of IAV-specific immune serum regardless of the amount transferred. When compared with responses in control groups and recipients of low and intermediate levels of convalescent serum, nucleoprotein-specific T cell responses in recipients of high levels of IAV-specific serum, which prevent overt weight loss and reduce peak viral titers in the lungs, are, however, markedly reduced. Although detectable at priming, this response recalls poorly and is unable to mediate protection against a lethal heterotypic (H3N2) virus challenge at later memory time points. A similar failure to generate protective heterosubtypic T cell immunity during IAV priming is seen in offspring of IAV-primed mothers that naturally receive high titers of IAV-specific Ab through maternal transfer. Our findings support that priming of protective heterosubtypic T cell responses can occur in the presence of intermediate levels of pre-existing Ab. These results have high relevance to vaccine approaches aiming to incorporate and evaluate cellular and humoral immunity towards IAV and other viral pathogens against which T cells can protect against variants escaping Ab-mediated protection.

Citing Articles

Effects of Influenza Vaccine on the Immune Responses to SARS-CoV-2 Vaccination.

Riccomi A, Trombetta C, Dorrucci M, Di Placido D, Sanarico N, Farchi F Vaccines (Basel). 2024; 12(4).

PMID: 38675807 PMC: 11054385. DOI: 10.3390/vaccines12040425.


Ex Pluribus Unum: The CD4 T Cell Response against Influenza A Virus.

Finn C, McKinstry K Cells. 2024; 13(7.

PMID: 38607077 PMC: 11012043. DOI: 10.3390/cells13070639.


Pre-existing CD4 T cell help boosts antibody responses but has limited impact on germinal center, antigen-specific B cell frequencies after influenza infection.

Besavilla D, Reusch L, Enriquez J, Schon K, Angeletti D Front Immunol. 2023; 14:1243164.

PMID: 37711622 PMC: 10499173. DOI: 10.3389/fimmu.2023.1243164.

References
1.
Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

2.
Benton K, Misplon J, Lo C, Brutkiewicz R, Prasad S, Epstein S . Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. J Immunol. 2001; 166(12):7437-45. DOI: 10.4049/jimmunol.166.12.7437. View

3.
Hurwitz J, Hackett C, McAndrew E, GERHARD W . Murine TH response to influenza virus: recognition of hemagglutinin, neuraminidase, matrix, and nucleoproteins. J Immunol. 1985; 134(3):1994-8. View

4.
Hoskins T, Davies J, Smith A, Miller C, Allchin A . Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital. Lancet. 1979; 1(8106):33-5. DOI: 10.1016/s0140-6736(79)90468-9. View

5.
Goel R, Painter M, Apostolidis S, Mathew D, Meng W, Rosenfeld A . mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021; 374(6572):abm0829. PMC: 9284784. DOI: 10.1126/science.abm0829. View